Non-Alcoholic Steatohepatitis (NASH)

Categories: Liver diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Non-Alcoholic Steatohepatitis

MalaCards integrated aliases for Non-Alcoholic Steatohepatitis:

Name: Non-Alcoholic Steatohepatitis 12 20 15 17
Nonalcoholic Steatohepatitis 20 15
Nash 12 20
Non-Alcoholic Fatty Liver Disease 20


External Ids:

Disease Ontology 12 DOID:0080547

Summaries for Non-Alcoholic Steatohepatitis

GARD : 20 Nonalcoholic steatohepatitis, or NASH, is a common, often "silent" liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly. NASH most often occurs in people who are middle aged and overweight or obese. Affected individuals may also have elevated levels of blood lipids (such as cholesterol and triglycerides) and many have diabetes or prediabetes. Treatment is centered around working towards a healthy lifestyle, including weight reduction, dietary modification, increased activity and avoidance of alcohol and unnecessary medications. The underlying cause of NASH remains unclear.

MalaCards based summary : Non-Alcoholic Steatohepatitis, also known as nonalcoholic steatohepatitis, is related to non-alcoholic fatty liver disease and fatty liver disease. An important gene associated with Non-Alcoholic Steatohepatitis is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Metabolism and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Atorvastatin and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and kidney, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Disease Ontology : 12 A nonalcoholic fatty liver disease that is characterized by the presence of inflammation with hepatocyte injury such as ballooning, with or without any fibrosis.

Related Diseases for Non-Alcoholic Steatohepatitis

Diseases related to Non-Alcoholic Steatohepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 801)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic fatty liver disease 32.2 TNF TLR4 SIRT1 PPARG PPARA PNPLA3
2 fatty liver disease 32.1 TNF PPARG PPARA PNPLA3 MTTP MIR122
3 gestational diabetes 31.6 TNF PPARG INS IL6 ADIPOQ
4 hyperandrogenism 31.6 PPARG INS ADIPOQ
5 congestive heart failure 31.5 TNF INS IL6 ALB
6 liver cirrhosis 31.5 TNF TLR4 PPARG PNPLA3 MIR122 INS
7 autoimmune hepatitis 31.5 TNF KRT18 GPT ALB
8 liver disease 31.5 TNF PPARA PNPLA3 NR1H4 MTTP MIR21
9 gastroesophageal reflux 31.5 TNF IL6 CCL2 ADIPOQ
10 hyperinsulinism 31.4 PPARG PPARA INS ADIPOQ
11 leptin deficiency or dysfunction 31.4 TNF PPARG PPARA INS IL6 CCL2
12 cholelithiasis 31.4 NR1H4 INS GPT ALB
13 microvascular complications of diabetes 3 31.4 MIR21 INS ALB
14 lipid metabolism disorder 31.4 PPARG PPARA NR1H4 MTTP MIR122 INS
15 viral hepatitis 31.3 TNF TLR4 PNPLA3 MIR122 KRT18 INS
16 hepatocellular carcinoma 31.3 TNF TLR4 PNPLA3 MIR21 MIR122 KRT18
17 hyperglycemia 31.3 PPARG INS IL6 ALB ADIPOQ
18 alcoholic hepatitis 31.3 TNF TLR4 PNPLA3 KRT18 IL6 GPT
19 hepatitis c 31.3 TNF MIR122 KRT18 GPT
20 hepatoblastoma 31.2 PPARA KRT18 IL6 CYP2E1
21 portal hypertension 31.2 TNF TLR4 PNPLA3 NR1H4 INS GPT
22 hyperthyroidism 31.2 INS IL6 GPT ALB
23 gout 31.2 TNF TLR4 INS IL6 ALB
24 cholangitis, primary sclerosing 31.1 TNF NR1H4 IL6 GPT ALB
25 end stage renal disease 31.1 TNF INS IL6 CCL2 ALB ADIPOQ
26 sleep disorder 31.1 TNF INS IL6 ALB ADIPOQ
27 placenta disease 31.1 TNF INS IL6 ADIPOQ
28 inflammatory bowel disease 31.1 TNF TLR4 PPARG PPARA NR1H4 MIR21
29 glucose intolerance 31.1 TNF PPARG INS IL6 GPT CCL2
30 wilson disease 31.1 TNF PNPLA3 IL6 GPT
31 diarrhea 31.1 TNF TLR4 IL6 GPT ALB
32 pre-eclampsia 31.1 TNF TLR4 INS IL6 ALB ADIPOQ
33 exanthem 31.1 TNF IL6 GPT ALB
34 stroke, ischemic 31.1 TNF TLR4 SIRT1 IL6 ALB
35 hyperuricemia 31.1 PPARG INS GPT ALB
36 crohn's disease 31.0 TNF TLR4 IL6 CCL2 ALB
37 choline deficiency disease 31.0 PPARA NR1H4 GPT
38 hypothyroidism 31.0 TNF INS GPT ALB ADIPOQ
39 sclerosing cholangitis 31.0 TNF TLR4 NR1H4 IL6 GPT ALB
40 coronary heart disease 1 31.0 MTTP INS ADIPOQ
41 alpha-1-antitrypsin deficiency 31.0 TNF GPT ALB
42 esophageal varix 31.0 INS GPT ALB
43 abdominal obesity-metabolic syndrome 1 31.0 PPARG PPARA NR1H4 MTTP MIR122 INS
44 skin disease 31.0 TNF PPARG PPARA MIR21 IL6 ALB
45 nasopharyngitis 31.0 TNF INS GPT
46 atherosclerosis susceptibility 31.0 TNF TLR4 PPARG PPARA INS IL6
47 sleep apnea 30.9 TNF INS IL6 GPT CCL2 ALB
48 immune deficiency disease 30.9 TNF MIR21 IL6 GPT CCL2
49 hepatic encephalopathy 30.9 TNF IL6 GPT ALB
50 peritonitis 30.9 TNF TLR4 IL6 CCL2 ALB

Graphical network of the top 20 diseases related to Non-Alcoholic Steatohepatitis:

Diseases related to Non-Alcoholic Steatohepatitis

Symptoms & Phenotypes for Non-Alcoholic Steatohepatitis

GenomeRNAi Phenotypes related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ACACA ALB CCL2 KRT18 MTTP NR1H4

MGI Mouse Phenotypes related to Non-Alcoholic Steatohepatitis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 ACACA ADIPOQ ALB CD36 CYP2E1 IL6
2 cardiovascular system MP:0005385 10.32 ADIPOQ ALB CD36 CYP2E1 IL6 INS
3 growth/size/body region MP:0005378 10.32 ACACA ADIPOQ CD36 CYP2E1 IL6 INS
4 liver/biliary system MP:0005370 10.27 ACACA ADIPOQ ALB CD36 CYP2E1 IL6
5 adipose tissue MP:0005375 10.26 ADIPOQ CD36 IL6 INS NR1H4 PNPLA3
6 immune system MP:0005387 10.25 ACACA ADIPOQ ALB CCL2 CD36 IL6
7 mortality/aging MP:0010768 10.2 ACACA ADIPOQ ALB CD36 CYP2E1 IL6
8 digestive/alimentary MP:0005381 10.1 ALB CD36 IL6 INS NR1H4 SIRT1
9 integument MP:0010771 10.06 ADIPOQ IL6 INS NR1H4 PPARA PPARG
10 muscle MP:0005369 9.91 ADIPOQ ALB CD36 IL6 INS PPARA
11 neoplasm MP:0002006 9.81 ADIPOQ ALB CYP2E1 IL6 NR1H4 PPARG
12 renal/urinary system MP:0005367 9.61 ADIPOQ ALB CD36 IL6 INS PPARA
13 skeleton MP:0005390 9.36 ADIPOQ CD36 CYP2E1 GPT IL6 INS

Drugs & Therapeutics for Non-Alcoholic Steatohepatitis

Drugs for Non-Alcoholic Steatohepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Atorvastatin Approved Phase 4 134523-00-5 60823
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
Glimepiride Approved Phase 4 93479-97-1 3476
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Amlodipine Approved Phase 4 88150-42-9 2162
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
Liraglutide Approved Phase 4 204656-20-2 44147092
Montelukast Approved Phase 4 158966-92-8 5281040
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
Gliclazide Approved Phase 4 21187-98-4 3475
Insulin detemir Approved Phase 4 169148-63-4 5311023
Insulin aspart Approved Phase 4 116094-23-6 16132418
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
Ribavirin Approved Phase 4 36791-04-5 37542
Phentermine Approved, Illicit Phase 4 122-09-8 4771
Empagliflozin Approved Phase 4 864070-44-0
Alogliptin Approved Phase 4 850649-61-5 11450633
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Tocopherol Approved, Investigational Phase 4 1406-66-2
Dulaglutide Approved, Investigational Phase 4 923950-08-7
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
Metformin Approved Phase 4 657-24-9 14219 4091
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Insulin glargine Approved Phase 4 160337-95-1
Saxagliptin Approved Phase 4 361442-04-8 11243969
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Metadoxine Experimental Phase 4 74536-44-0
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
37 Ipragliflozin Investigational Phase 4 761423-87-4
38 Tocotrienol Investigational Phase 4 6829-55-6
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
40 Antihypertensive Agents Phase 4
41 Vasodilator Agents Phase 4
42 Anti-HIV Agents Phase 4
43 Anti-Retroviral Agents Phase 4
44 Giapreza Phase 4
45 Angiotensin II Type 1 Receptor Blockers Phase 4
46 Angiotensinogen Phase 4
47 Angiotensin Receptor Antagonists Phase 4
48 carnitine Phase 4
49 Angiotensin-Converting Enzyme Inhibitors Phase 4
50 Reverse Transcriptase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 906)
# Name Status NCT ID Phase Drugs
1 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
2 Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Unknown status NCT02649465 Phase 4 Tofogliflozin;Glimepiride
3 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
4 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
5 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
6 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Unknown status NCT02051842 Phase 4 Metadoxine
7 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
8 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
9 Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Unknown status NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
10 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
11 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
12 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
13 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
14 Clinical Study Evaluating the Efficacy and Safety of Montelukast in the Treatment of Non-Alcoholic Steatohepatitis (NASH) Completed NCT04537780 Phase 4 Montelukast
15 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
16 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
17 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
18 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
19 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
20 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
21 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
22 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
23 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
24 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
25 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
26 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
27 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
28 Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease:an Multicenter,Randomized, Double-blind, Parallel- Controlled Study. Completed NCT03796975 Phase 4 Combination of Pioglitazone and Metformin Tablets;Metformin Hydrochloride Tablets
29 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
30 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
31 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
32 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
33 Effectiveness and Tolerability of Phentermine in the Reduction of Intrahepatic Fat Infiltration, Adipose Tissue and Postoperative Complications in Patients Under Bariatric Surgery Completed NCT03849729 Phase 4 Phentermine
34 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
35 To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes: A Prospective, Open-Label, Single-Arm, Single-Center Clinical Study Recruiting NCT03950505 Phase 4 Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
36 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial Recruiting NCT03198572 Phase 4 Placebo;Berberine
37 Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver Recruiting NCT03646292 Phase 4 Pioglitazone;Empagliflozin;Combination of pioglitazone and empagliflozin
38 S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease Recruiting NCT04718051 Phase 4 Shen Pu Yang Gan Wan;Placebo
39 The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD) - a Randomized-controlled Trial - Recruiting NCT04465032 Phase 4
40 A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases Enrolling by invitation NCT03910361 Phase 4 Evogliptin;Pioglitazone
41 A Multicentre Controlled and Randomized Study Assessing the Effect of Dulaglutide add-on to Dietary Reinforcement Versus Dietary Reinforcement Alone in Patients With Type 2 Diabetes and Carriers of a Non-alcoholic Steatohepatitis Not yet recruiting NCT03648554 Phase 4 dulaglutide (TRULICITY®) 1.5 mg
42 Combined Active Treatment in Type 2 Diabetes With NASH Not yet recruiting NCT04639414 Phase 4 Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector;Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide;Placebo matching empagliflozin and placebo pen injector matching semaglutide
43 Effect of Empagliflozin on Liver Fat in Non-alcoholic Fatty Liver Disease Patients Without Diabetes Mellitus: a Randomized, Double-blind, Placebo-controlled Trial Not yet recruiting NCT04642261 Phase 4 Empagliflozin 10 MG;Placebo pills
44 Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases: A Randomized Placebo-controlled Clinical Trial Not yet recruiting NCT04475276 Phase 4 Placebo;Alphalipoic acid
45 Body Composition and Metabolic Manifestations of Insulin Resistance in Adolescents With Polycystic Ovary Syndrome: Ectopic Fat Deposition and Metabolic Markers: Intervention and Follow-up Portion Suspended NCT02500147 Phase 4 Metformin;Placebo
46 RiFL: Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)? Terminated NCT01355575 Phase 4 Rifaximin
47 Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH (Non-alcoholic Steato-hepatitis) Terminated NCT01406704 Phase 4 Rosiglitazone;alpha-lipoic acid;Rosiglitazone/alpha-lipoic acid
48 Hyperinsulinemia and Insulin Resistance in Nonalcoholic Fatty Liver Disease. Metformin for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial Terminated NCT00736385 Phase 4 Glucophage (Metformin);Placebo
49 A Phase IV, Open Label, Randomized Trial on the Effect of Metformin Plus Lantus Insulin, Pioglitazone, or DPP4 Inhibitor on Fatty Liver in Patients With Type II Diabetes Terminated NCT02365233 Phase 4 DPP4 inhibitor;Pioglitazone;Lantus insulin
50 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle

Search NIH Clinical Center for Non-Alcoholic Steatohepatitis

Genetic Tests for Non-Alcoholic Steatohepatitis

Anatomical Context for Non-Alcoholic Steatohepatitis

MalaCards organs/tissues related to Non-Alcoholic Steatohepatitis:

Liver, Endothelial, Kidney, Ovary, T Cells, Skeletal Muscle, Neutrophil

Publications for Non-Alcoholic Steatohepatitis

Articles related to Non-Alcoholic Steatohepatitis:

(show top 50) (show all 9455)
# Title Authors PMID Year
Exome-wide scan identifies significant association of rs4788084 in IL27 promoter with increase in hepatic fat content among Indians. 61
33444683 2021
Prolyl endopeptidase disruption reduces hepatic inflammation and oxidative stress in methionine-choline-deficient diet-induced steatohepatitis. 61
33516698 2021
MR cell size imaging with temporal diffusion spectroscopy. 61
33338562 2021
Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. 61
33482185 2021
Long non-coding RNA Meg3 deficiency impairs glucose homeostasis and insulin signaling by inducing cellular senescence of hepatic endothelium in obesity. 61
33508742 2021
Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin. 61
33268842 2021
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. 61
33275980 2021
Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis. 61
33342543 2021
Hepatic metabolic adaptation and adipose tissue expansion are altered in mice with steatohepatitis induced by high-fat high sucrose diet. 61
33264665 2021
Evaluation of the histological variability of core and wedge biopsies in nonalcoholic fatty liver disease in bariatric surgical patients. 61
32170564 2021
Interleukin-2 receptor alpha as a biomarker for nonalcoholic fatty liver disease diagnosis. 61
33306598 2021
Sudden cardiac death following liver transplantation: Incidence, trends and risk predictors. 61
33253736 2021
Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features. 61
33038431 2021
Functional long non-coding RNAs in hepatocellular carcinoma. 61
33129957 2021
Impact of laparoscopic sleeve gastrectomy on fibrosis stage in patients with child-A NASH-related cirrhosis. 61
32152677 2021
African Americans have a distinct clinical and histologic profile with lower prevalence of NASH and advanced fibrosis relative to Caucasians. 61
32317586 2021
Effects of renalase deficiency on liver fibrosis markers in a nonalcoholic steatohepatitis mouse model. 61
33495844 2021
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. 61
32531342 2021
Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications. 61
33358254 2021
Sacran, a sulfated polysaccharide, suppresses the absorption of lipids and modulates the intestinal flora in non-alcoholic steatohepatitis model rats. 61
33417955 2021
Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. 61
33038434 2021
Reply to: "Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications". 61
33386162 2021
Vesicular ATP release from hepatocytes plays a role in the progression of nonalcoholic steatohepatitis. 61
33212187 2021
Low real-world eligibility rates for nonalcoholic steatohepatitis patients for phase 3 clinical trial criteria application in a large academic health system. 61
32433419 2021
Dietary lycopene attenuates cigarette smoke-promoted nonalcoholic steatohepatitis by preventing suppression of antioxidant enzymes in ferrets. 61
33548472 2021
Therapeutic potential of puerarin against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis determined by combination of 1H NMR spectroscopy-based metabonomics and 16S rRNA gene sequencing. 61
33601157 2021
SMN depleted mice offer a robust and rapid onset model of non-alcoholic fatty liver disease. 61
33545428 2021
Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists. 61
33422984 2021
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. 61
33038432 2021
Cordycepin Ameliorates Nonalcoholic Steatohepatitis via Activation of AMP-Activated Protein Kinase Signaling Pathway. 61
33576035 2021
ER stress-induced adipocytes secrete-aldo-keto reductase 1B7-containing exosomes that cause nonalcoholic steatohepatitis in mice. 61
33359683 2021
NLRP3 deficiency did not attenuate NASH development under high fat calorie diet plus high fructose and glucose in drinking water. 61
33526807 2021
Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD. 61
33596938 2021
Abnormal fucosylation of alpha-fetoprotein in patients with non-alcoholic steatohepatitis. 61
33596344 2021
Influence of cardiometabolic comorbidities on myocardial function, infarction, and CARDIOPROTECTION: Role of cardiac redox signaling. 61
33588049 2021
Editorial: Emerging metabolic and transcriptomic signature of PNPLA3 associated NASH. 61
33544416 2021
Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. 61
33556256 2021
Transcriptional regulation of metabolic pathways via lipid-sensing nuclear receptors. 61
33545430 2021
The Impact of Ramadan Fasting on Fatty Liver Disease Severity: A Retrospective Case Control Study from Israel. 61
33595214 2021
Elastographic liver evaluation of Katukyadi churna in the management of Non-Alcoholic Steatohepatitis (NASH) - A single arm clinical trial. 61
33579578 2021
Impact of liver-specific GLUT8 silencing on fructose-induced inflammation and omega oxidation. 61
33554072 2021
Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models. 61
33244884 2021
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? 61
33548031 2021
Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM. 61
33568418 2021
Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. 61
33546130 2021
Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease. 61
33557653 2021
Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. 61
33592199 2021
Electron microscopic observations in perfusion-fixed human non-alcoholic fatty liver disease biopsies. 61
33143903 2021
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? 61
33541866 2021
Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease. 61
32918399 2021

Variations for Non-Alcoholic Steatohepatitis

Expression for Non-Alcoholic Steatohepatitis

Search GEO for disease gene expression data for Non-Alcoholic Steatohepatitis.

Pathways for Non-Alcoholic Steatohepatitis

Pathways related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.22 TNF TLR4 IL6 CD36
8 12.19 TNF TLR4 IL6 CCL2
Show member pathways
10 12.05 TNF TLR4 IL6 CCL2
12 11.96 TNF TLR4 IL6 CCL2
13 11.93 TNF IL6 CD36 CCL2
15 11.82 TNF TLR4 IL6 CCL2
Show member pathways
Show member pathways
11.72 TNF TLR4 IL6
18 11.72 TNF TLR4 IL6
21 11.65 TNF SIRT1 PPARG
22 11.63 TNF IL6 CCL2
24 11.58 TNF TLR4 IL6 CD36
25 11.57 TNF TLR4 IL6
26 11.49 TNF IL6 CCL2
27 11.48 TNF TLR4 CCL2
28 11.32 TNF TLR4 IL6
30 11.27 TLR4 CD36 CCL2
32 11.05 TNF TLR4 IL6 CD36 CCL2
33 10.87 TNF CD36 CCL2
35 10.71 SIRT1 PPARG

GO Terms for Non-Alcoholic Steatohepatitis

Cellular components related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 TNF MIR21 MIR122 KRT18 INS IL6
2 receptor complex GO:0043235 9.35 TLR4 PPARG NR1H4 MTTP CD36

Biological processes related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.26 TNF TLR4 SIRT1 PPARG PPARA NR1H4
2 immune response GO:0006955 10.14 TNF TLR4 IL6 CD36 CCL2
3 lipid metabolic process GO:0006629 10.12 PPARG PNPLA3 MTTP CYP2E1 CD36 ACACA
4 negative regulation of apoptotic process GO:0043066 10.11 SIRT1 NR1H4 MIR21 KRT18 IL6 ALB
5 inflammatory response GO:0006954 10.1 TNF TLR4 NR1H4 IL6 CCL2
6 positive regulation of gene expression GO:0010628 10.1 TNF TLR4 MIR21 INS IL6 CD36
7 positive regulation of apoptotic process GO:0043065 10.07 TNF SIRT1 PPARG MIR21 IL6
8 positive regulation of protein phosphorylation GO:0001934 10.02 TNF SIRT1 MIR21 ADIPOQ
9 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10 TNF TLR4 CD36 ADIPOQ
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 TNF TLR4 MIR21 CD36 CCL2
11 fatty acid metabolic process GO:0006631 9.95 PPARG PPARA CYP2E1 CD36 ACACA
12 negative regulation of inflammatory response GO:0050728 9.94 PPARG PPARA NR1H4 ADIPOQ
13 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.92 TLR4 MIR21 ADIPOQ
14 cellular response to insulin stimulus GO:0032869 9.92 PPARG PNPLA3 GPT ADIPOQ
15 negative regulation of tumor necrosis factor production GO:0032720 9.91 TLR4 NR1H4 ADIPOQ
16 negative regulation of interleukin-6 production GO:0032715 9.91 TNF TLR4 NR1H4
17 cellular response to starvation GO:0009267 9.9 SIRT1 PPARA ALB
18 response to glucocorticoid GO:0051384 9.9 TNF IL6 ADIPOQ
19 glucose metabolic process GO:0006006 9.89 TNF INS ADIPOQ
20 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.89 TNF SIRT1 MIR21 INS
21 humoral immune response GO:0006959 9.88 TNF IL6 CCL2
22 positive regulation of interleukin-6 production GO:0032755 9.88 TNF TLR4 IL6 CD36
23 positive regulation of interleukin-1 beta production GO:0032731 9.87 TNF TLR4 IL6
24 positive regulation of cytokine production GO:0001819 9.87 TNF MIR21 INS
25 negative regulation of I-kappaB kinase/NF-kappaB signaling GO:0043124 9.86 SIRT1 NR1H4 ADIPOQ
26 lipid homeostasis GO:0055088 9.85 PPARG PNPLA3 ACACA
27 negative regulation of signaling receptor activity GO:2000272 9.83 TNF PPARG PPARA
28 positive regulation of nitric oxide biosynthetic process GO:0045429 9.83 TNF TLR4 CD36
29 intracellular receptor signaling pathway GO:0030522 9.83 PPARG PPARA NR1H4
30 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 TNF TLR4 INS IL6 CD36
31 positive regulation of chemokine production GO:0032722 9.82 TNF TLR4 IL6
32 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 TNF TLR4 CCL2
33 positive regulation of insulin receptor signaling pathway GO:0046628 9.77 SIRT1 NR1H4 INS
34 positive regulation of MHC class II biosynthetic process GO:0045348 9.74 TLR4 SIRT1
35 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.74 TNF TLR4
36 cellular response to lipoteichoic acid GO:0071223 9.74 TLR4 CD36
37 positive regulation of macrophage cytokine production GO:0060907 9.74 TLR4 CD36
38 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.74 PPARA MIR21 INS
39 negative regulation of cholesterol storage GO:0010887 9.73 PPARG PPARA
40 positive regulation of NLRP3 inflammasome complex assembly GO:1900227 9.73 TLR4 CD36
41 negative regulation of lipid storage GO:0010888 9.73 TNF IL6
42 response to lipid GO:0033993 9.73 PPARG PPARA CD36
43 regulation of lipid storage GO:0010883 9.72 SIRT1 PPARA
44 negative regulation of acute inflammatory response GO:0002674 9.72 PPARG INS
45 response to bacterium GO:0009617 9.72 TLR4 CYP2E1 CD36 CCL2 ADIPOQ
46 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.71 MIR21 IL6
47 cellular triglyceride homeostasis GO:0035356 9.71 SIRT1 NR1H4
48 interleukin-1 beta production GO:0032611 9.71 TLR4 CD36
49 vascular endothelial growth factor production GO:0010573 9.71 TNF IL6
50 fatty acid homeostasis GO:0055089 9.71 SIRT1 NR1H4 INS

Molecular functions related to Non-Alcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 TNF TLR4 SIRT1 PPARG INS ALB
2 cytokine activity GO:0005125 9.46 TNF IL6 CCL2 ADIPOQ
3 nuclear receptor activity GO:0004879 8.8 PPARG PPARA NR1H4

Sources for Non-Alcoholic Steatohepatitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....